- 2017April 06
GMA301 was selected as “National Mega-Innovative Program”
April 6, 2017, GMA301 was selected as the “National Mega-Innovative Program” for the 13th Five Year Plan.
- 2017June 01
GMA102/105 entered phase 2 clinical trial in Australia and New Zealand
June 1, 2017, GMA102/105 has started phase Ib/IIa clinical trial in Australia and New Zealand.
- 2017October 05
GMAX to Present at the International Diabetes Federation Congress 2017
October 5, 2017, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today...
- 2017December 07
First Patient Dose of GMA102 in the Phase II Clinical Trial for Treatment of Type 2 Diabetes
December 7, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today ...
- 2017December 16
GMAX Initiates First-in-human Trial of GMA301 in Australia
December 16, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today ...